A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer - PubMed (original) (raw)
. 1999 Apr 8;18(14):2335-41.
doi: 10.1038/sj.onc.1202540.
Affiliations
- PMID: 10327053
- DOI: 10.1038/sj.onc.1202540
A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer
G Strathdee et al. Oncogene. 1999.
Abstract
Experimental evidence from several sources has identified a link between mismatch repair deficiency and cytotoxic drug resistance. Selection for cisplatin resistance in the human ovarian cancer cell line A2780, results in loss of expression of the mismatch repair protein hMLH1 in most (90%) of the resultant cisplatin-resistant cell lines. Here we demonstrate that the cisplatin sensitive parental cell line displays methylation of the promoter of only one hMLH1 allele, but that the resistant cell lines all exhibit hyper-methylation of the promoters of both hMLH1 alleles. Full methylation of all sites tested was found to be invariably associated with loss of hMLH1 expression, whereas a partial increase in methylation appears compatible with either loss or maintenance of expression. In addition treatment of two of the resistant cell lines with 5-azacytidine, a known inhibitor of methylation, results in re-expression of hMLH1. Clonogenic assays demonstrate that the 5-azacytidine treated cells show increased sensitivity to cisplatin. Furthermore, 12.5% (3/ 24) of ovarian tumours show hypermethylation of the hMLH1 promoter. Expression of hMLH1 is absent in the tumours that are hypermethylated, while all the unmethylated tumours still express the protein. This analysis suggests that methylation of the hMLH1 promoter may be a common mechanism for loss of hMLH1 expression, and possibly for cisplatin-resistance, in ovarian cancer.
Similar articles
- Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter.
Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R. Plumb JA, et al. Cancer Res. 2000 Nov 1;60(21):6039-44. Cancer Res. 2000. PMID: 11085525 - Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling.
Zeller C, Dai W, Steele NL, Siddiq A, Walley AJ, Wilhelm-Benartzi CS, Rizzo S, van der Zee A, Plumb JA, Brown R. Zeller C, et al. Oncogene. 2012 Oct 18;31(42):4567-76. doi: 10.1038/onc.2011.611. Epub 2012 Jan 16. Oncogene. 2012. PMID: 22249249 - Expression and promoter methylation status of mismatch repair gene hMLH1 and hMSH2 in epithelial ovarian cancer.
Zhang H, Zhang S, Cui J, Zhang A, Shen L, Yu H. Zhang H, et al. Aust N Z J Obstet Gynaecol. 2008 Oct;48(5):505-9. doi: 10.1111/j.1479-828X.2008.00892.x. Aust N Z J Obstet Gynaecol. 2008. PMID: 19032668 - hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents.
Brown R, Hirst GL, Gallagher WM, McIlwrath AJ, Margison GP, van der Zee AG, Anthoney DA. Brown R, et al. Oncogene. 1997 Jul 3;15(1):45-52. doi: 10.1038/sj.onc.1201167. Oncogene. 1997. PMID: 9233776
Cited by
- Role of Epigenetics for the Efficacy of Cisplatin.
Lumpp T, Stößer S, Fischer F, Hartwig A, Köberle B. Lumpp T, et al. Int J Mol Sci. 2024 Jan 17;25(2):1130. doi: 10.3390/ijms25021130. Int J Mol Sci. 2024. PMID: 38256203 Free PMC article. Review. - The role of DNA methylation in ovarian cancer chemoresistance: A narrative review.
Song K, Artibani M. Song K, et al. Health Sci Rep. 2023 Apr 27;6(5):e1235. doi: 10.1002/hsr2.1235. eCollection 2023 May. Health Sci Rep. 2023. PMID: 37123549 Free PMC article. - CD80 DNA methylation and single-nucleotide polymorphism associated with clopidogrel response: a whole-genome DNA methylation analysis in acute coronary syndrome.
Song PY, Li MP, Peng LM, Chen XP. Song PY, et al. Res Pract Thromb Haemost. 2023 Feb 24;7(2):100093. doi: 10.1016/j.rpth.2023.100093. eCollection 2023 Feb. Res Pract Thromb Haemost. 2023. PMID: 36970128 Free PMC article. - Epigenetic Regulation Towards Acquired Drug Resistance in Cancer.
Ketkar M, Dutt S. Ketkar M, et al. Subcell Biochem. 2022;100:473-502. doi: 10.1007/978-3-031-07634-3_14. Subcell Biochem. 2022. PMID: 36301503 - SETD1A-SOX2 axis is involved in tamoxifen resistance in estrogen receptor α-positive breast cancer cells.
Jin ML, Yang L, Jeong KW. Jin ML, et al. Theranostics. 2022 Jul 18;12(13):5761-5775. doi: 10.7150/thno.72599. eCollection 2022. Theranostics. 2022. PMID: 35966598 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical